Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to Tumor Necrosis Factor α

Cancer Research

Volumn 63, Issue 12, 2003, Pages 3202-3210

  Halin, Cornelia ^a   Gafner, Verina ^a   Villani, Maria Elena ^a   Borsi, Laura ^b   Berndt, Alexander ^c   Kosmehl, Hartwig ^d   Zardi, Luciano ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; FIBRONECTIN; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 12; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L19; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER REGRESSION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TERATOCARCINOMA; TOXICITY TESTING; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; IMMUNOCONJUGATES; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; MICE; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TERATOCARCINOMA; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 0037731516     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature (Lond.), 411: 380-384, 2001.
2. Borden, E. C., and Sondel, P. M. Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer (Phila.), 65: 800-814, 1990.
3. Oppenheim, J. J., Murphy, W. J., Chertox, O., Schirrmacher, V., and Wang, J. M. Prospects for cytokine and chemokine biotherapy. Clin. Cancer Res., 3: 2682-2686, 1997.
4. Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., and Lejeune, F. J. High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10: 52-60, 1992.
5. Eggermont, A. M., Schraffordt Koops, H., Lienard, D., Kroon, B. B., van Geel, A. N., Hoekstra, H. J., and Lejeune, F. J. Isolated limb perfusion with high dose tumor necrosis factor α in combination with interferon γ, and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol., 14: 2653-2665, 1996.
6. Eggermont, A. M. TNF registered in Europe: does TNF get a second chance? J. Immunother., 23: 505-506, 2000.
7. Lode, H. N., Xiang, R., Dreier, T., Varki, N. M., Gillies, S. D., and Reisfeld, R. A. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood, 91: 1706-1715, 1998.
8. Gillies, S. D., Lan, Y., Wesolowski, J. S., Qian, X., Reisfeld, R. A., Holden, S., Super, M., and Lo, K. M. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J. Immunol., 160: 6195-6203, 1998.
9. Peng, L. S., Penichet, M. L., and Morrison, S. L. A single chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol., 163: 250-258, 1999.
10. Cooke, S. P., Pedley, R. B., Boden, R., Begent, R. H., and Chester, K. A. In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor α fusion protein. Bioconjug. Chem., 13: 7-15, 2002.
11. Zardi, L., Carnemolla, B., Siri, A., Petersen, T. E., Paolella, G., Sebastio, G., and Baralle, F. E. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J., 6: 2937-2342, 1987.
12. Carnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., Bigotti, A., and Natali, P. G. A tumor associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol., 108: 1139-1148, 1989.
13. Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., and Zardi, L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer. 59: 612-618, 1994.
14. Kaczmarek, J., Castellani, P., Nicolo, G., Spina, B., Allemanni, G., and Zardi, L. Distribution of oncofetal fibronectin isofoms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer, 59: 11-16, 1994.
15. Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., and Neri, D. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol., 20: 264-269, 2002.
16. Khawli, L. A., Miller, G. K., and Epstein, A. L. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer (Phila.), 73: 824-831, 1994.
17. Folli, S., Pelegrin, A., Chalandon, Y., Yao, X., Buchegger, F., Lienard, D., Lejeune, F., and Mach, J. P. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int. J. Cancer, 53: 829-836, 1993.
18. Holliger, P., Prospero, T., and Winter, G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA, 90: 6444-6448, 1993.
19. Lode, H. N., Xiang, R., Duncan, S. R., Theofilopoulos, A. N., Gilies, S. D., and Reisfeld, R. A. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc. Natl. Acad. Sci. USA, 96: 8591-8596, 1999.
20. Wigginton, J. M., Park. J. W., Grays, M. E., Young, H. A., Jorcyk, C. L., Back, T. C., Brunda, M. J., Strieter, R. M., Ward, J., Green, J. E., and Wiltrout, R. H. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration. Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J. Immunol., 166: 1156-1168, 2001.
21. Vagliani, M., Rodolfo, M., Cavallo, F., Parenza, M., Melani, C., Palmiani, G., Forni, G., and Colombo, M. P. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res., 56: 467-470, 1996.
22. Zagozdzon, R., Stoklosa, T., Golab, J., Giermasz, A., Dabrowska, A., Lasek, W., and Jakobisiak, M. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor α in a murine melanoma model. Anticancer Res., 17: 4493-4498, 1997.
23. Taniguchi, F., Yamagishi, H., Fujiwara, H., Ueda, Y., Fuji, N., Yoshimura, T., and Oka, T. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine. Gene Ther., 5: 1677-1684, 1998.
24. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., and Folkman, J. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. (Bethesda) 87: 581-586, 1995.
25. Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D., and Allison, A. C. Dual role of tumor necrosis factor α in angiogenesis. Am. J. Pathol. 140: 539-544, 1992.
26. Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., and Urushizaki, I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res., 48: 2179-2183, 1988.
27. Renard, N., Lienard, D., Lespagnard, L., Eggermont, A., Heimann, R., and Lejeune, F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor α (rTNF α). Int. J. Cancer, 57: 656-663, 1994.
28. Smyth, M. J., Pietersz, G. A., and McKenzie, I. F. Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo. Cancer Res., 48: 3607-3612, 1988.
29. Kirchhofer, D. Sakariassen, K. S., Clozel, M., Tschopp, T. B., Hadvary, P., Nemerson, Y., and Baumgartner, H. R. Relationship between tissue factor expression and deposition of fibrin, platelets, and leukocytes on cultured endothelial cells under venous blood flow conditions. Blood, 8l: 2050-2058, 1993.
30. Shimomura, K., Manda, T., Mukumoto, S., Kobayashi, K., Nakano, K. and Mori, J. Recombinant human tumor necrosis factor α: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer, 41: 243-247, 1988.
31. Nooijen, P. T., Manusama, E. R., Eggermont, A. M., Schalkwijk, L., Stavast, J., Marquet, R. L., de Waal, R. M., and Ruiter, D. J. Synergistic effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br. J. Cancer, 74: 1908-1915, 1996.
32. Olieman, A. F., van Ginkel, R. J., Hoesktra, H. J., Mooyaart, E. L., Molenaar, W. M., and Koops, H. S. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann. Surg. Oncol., 4: 64-69, 1997.
33. Sato, N., Goto, T., Haranaka, K. Satomi, N., Nariuchi, H., Mano-Hirano, Y., and Sawasaki, Y. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J. Natl. Cancer Inst. (Bethesda), 76: 1113-1121, 1986.
34. de Wilt, J. H., ten Hagen, T. L., de Boeck, G., van Tiel, S. T., de Bruijn, E. A., and Eggermont, A. M. Tumour necrosis factor α increases melphalan concentration in tumour tissue after isolated limb perfusion. Br. J. Cancer, 82: 1000-1003, 2000.
35. Birchler, M., Viti, F., Zardi, L., Spiess, B., and Neri, D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat. Biotechnol., 17: 984-988, 1999.
36. Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., and Zardi, L. Enhancement of the antitumor properties of interleukin 2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood, 99: 1659-1665, 2002.
37. Demartis, S., Tarli, L., Bood, L., Zardi, L., and Neri, D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucl. Med., 28: 534-539, 2001.
38. Nilsson, F., Kosmehl, H., Zardi, L., and Neri, D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res., 61: 711-716, 2001.
39. Tarli, L., Balza, E., viti, F., Borsi, L., Castellani, P., Berndorff, D., Dinkelborg, L., Neri, D. and Zardi, L. A high affinity human antibody that targets tumoral blood vessels. Blood, 94: 192-198, 1999.
40. Viti, F., Tarli, L., Giovannoni, L., Zardi, L., and Neri, D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res., 59: 347-352, 1999.
41. Santimaria, M., Moscatelli, G., Giovannoni, L., Viti, F., Leprini, A., Borsi, L., Neri, D., Zardi, L., and Riva, P. Immunoscintigraphic detection of angiogenesis in patients with cancer. Clin. Cancer Res., 9: 741-749.
42. Bernstine, E. G., Hooper, M. L., Grandchamps, S. and Ephrussi, B. Alkaline phosphatase activity in mouse teratoma. Proc. Natl. Acad. USA, 70: 3899-3903, 1973.
43. Neri, D., Petrul, H., Winter, G., Light, Y., Marais, R., Britton, K. E., and Creighton, A. M. Radioactive labeling of recOmbinant antibody fragments by phosphorylation using human casein kinase II arid [γ-32P]-ATP. Nat. Biotechnol. 14: 485-490, 1996.
44. Gately, M. K., Chizzonite, R., Presky, H. D. Measurement of human and mouse interleukin-12. New York: Current Protocols in Immunology, 1995, section 6.16.1; section 3.11.1.
45. Corti, A., Poiesi, C., Merli, S., and Cassani, G. Tumor necrosis factor (TNF) α quantification by ELISA and bioassay: effects of TNF α-soluble TNF receptor (p55) complex dissociation during assay incubations. J. Immunol. Methods, 177: 191-198, 1994.
46. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36: 59-74, 1977.
47. van Elsas, A., Hurwitz, A. A., and Allison, J. P. Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med., 190: 355-366, 1999.
48. van Elsas, A., Sutmuller, R. P., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J. P., Overwijk, W. W., Restifo, N. P., Melief, C. J., Offringa, R., and Allison, J. P. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med., 194: 481-489, 2001.
49. Halin, C., Niesner, U., Villani, M. E., Zardi, L., and Neri, D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int. J. Cancer, 102: 109-116, 2002.
50. Melkko, S., Halin, C., Borsi, L., Zardi, L., and Neri, D., An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int. J. Radiat. Oncol. Biol. Phys., 54: 1485-1490, 2002.